Distigmin Non-Exclusive Rebate Agreement
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Distigmin (ATC-Code nach WHO: N07AA03)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
15 / 100
Risk factors
Quantities are unknown and dependent on prescription behavior and patient numbers. No minimum volumes guaranteed.
The buyer may terminate the open-house procedure if exclusive agreements are concluded, typically 8-12 months after pub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Supply of pharmaceutical products containing the active substance Distigmin (ATC N07AA03).
- Non-exclusive rebate agreement under §130a Abs. 8 SGB V.
Show full summary
This is an open-house model (non-competitive) for non-exclusive pharmaceutical rebate agreements under §130a Abs.8 SGB V for the active substance Distigmin (ATC N07AA03). The buyer is AOK PLUS, covering Saxony and Thuringia. No estimated value is provided; quantities are unknown and no minimum volumes are guaranteed. The agreement runs until 31 October 2026. Participation is open to any pharmaceutical manufacturer meeting the conditions, with rolling submission deadlines. This is not a typical public procurement but a voluntary transparency notice.
Risks
Quantities are unknown and dependent on prescription behavior and patient numbers. No minimum volumes guaranteed.
The buyer may terminate the open-house procedure if exclusive agreements are concluded, typically 8-12 months after pub...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Pharmaceutical manufacturer as defined in §4 Abs.18 AMG.
- Company must have its seat in Germany, EU, or EEA (§9 Abs.2 AMG).
- No minimum volume or exclusivity; quantities are demand-driven.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Distigmin Non-Exclusive Rebate Agreement
Non-exclusive rebate agreement for pharmaceutical products containing Distigmin (ATC N07AA03). No guaranteed quantities. Contract ends 31 October 2026.
Location
Duration
Category
Award Criteria
Deadline
Award details
No explicit award criteria provided
the open-house model implies acceptance of all eligible participants without competitive evaluation.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Distigmin (ATC-Code nach WHO: N07AA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 15 Aug 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 492346-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
15 / 100
Risk factors
Quantities are unknown and dependent on prescription behavior and patient numbers. No minimum volumes guaranteed.
The buyer may terminate the open-house procedure if exclusive agreements are concluded, typically 8-12 months after pub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications